Drug intelligence / Profile preview

Bienenyaku A

Development stage
Unknown
Lead developer
Kokando Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Bienenyaku A is an over-the-counter (OTC) combination drug developed by Kokando Pharmaceutical for the symptomatic relief of allergic rhinitis, acute rhinitis, and sinusitis. Marketed under the "Kunihiro" brand, it contains a blend of active ingredients designed to address multiple symptoms: d-chlorpheniramine maleate acts as an antihistamine to reduce sneezing and runny nose; pseudoephedrine hydrochloride serves as a decongestant to alleviate nasal congestion; belladonna total alkaloids provide anticholinergic effects to suppress excess nasal secretion; dipotassium glycyrrhizinate acts as an anti-inflammatory agent; and anhydrous caffeine is included to counteract potential drowsiness and assist in symptom relief. It is administered orally in tablet form.

Brand names
鼻炎薬A「クニヒロ」Bienenyaku AKunihiro
Other names
Nasal medicine ABieneiyaku A
02

Targets

HSD11B2 (11β-HSD2)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)ADOR (Adenosine receptors)ADRA1A (α1A)

Beyond the preview

Go deeper on Bienenyaku A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bienenyaku A.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call